We’re all familiar with the life-saving impact of pacemakers and defibrillators on the heart. But we are just discovering that tiny doses of electricity applied to the body’s nervous system can treat disorders as diverse as asthma, diabetes, arthritis and high blood pressure. This ability has spawned a whole new field, called bioelectronic medicine.
Kris Famm on Bioelectronics
GSK is leading research into this new scientific field, which would not involve pills or injections, but miniaturised, implantable devices. Innovation is fundamental to driving improvements in healthcare, and our researchers are pursuing the latest scientific avenues and technologies so we can continue to develop medical breakthroughs for patients.
Introducing Galvani Bioelectronics
We’ve joined forces with Verily Life Sciences, a sister company of Google, to launch Galvani Bioelectronics – a company dedicated to the research, development and commercialisation of these medicines.
Bioelectronic medicine is a vision far from today’s medical practice. But we believe that one day these tiny devices, smaller than grains of rice, could be used to treat a range of chronic diseases, with greater precision and fewer side effects than with conventional medicines.